Fertility Preservation in Female and Male Benign and Malignant Conditions: 2nd Edition

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Reproductive and Developmental Biology".

Deadline for manuscript submissions: 30 June 2024 | Viewed by 854

Special Issue Editors


E-Mail Website
Guest Editor
Wales Fertility Institute, University Hospital of Wales, Cardiff University, Cardiff, UK
Interests: infertility; ultrasound
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Wales Fertility Institute, University Hospital of Wales, Cardiff University, Cardiff, UK
Interests: infertility; obstetrics and gynecology
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Mediclinic City Hospital, Dubai, United Arab Emirates
Interests: laparoscopy; uro0oncology; andrology

Special Issue Information

Dear Colleagues,

The number of cancer survivors has continually increased in recent years, with cancer survival doubling in the last 40 years; this is particularly true for cancers that affect a younger population, such as testicular cancer, childhood lymphoblastic leukaemia, and Hodgkin’s lymphoma, as well as breast cancer. However, these survivors will experience both short- and long-term sequelae of treatment, including sub-fertility or infertility. For this reason, many male and female cancer patients will be given the option of sperm, egg, embryo or ovarian tissue cryopreservation before commencing their treatment to protect or restore fertility in the future; this is also true for benign conditions affecting women, such as endometriosis, dermoids, fibroids and autoimmune/haematological diseases.

This Special Issue aims to present the latest advances in the cross-disciplinary field of oncofertility. We welcome contributions from all specialists involved in the different options of fertility preservation in male and female patients affected by benign and malignant conditions that can impair their fertility in future.

For the publication of the previous edition, please see https://www.mdpi.com/journal/life/special_issues/ZIOIO70963.

Dr. Arianna D’Angelo
Dr. Suman Dadhich
Dr. Ali Thwaini
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • oncofertility
  • fertility preservation
  • cancer
  • oncology
  • fertility
  • egg freezing
  • embryo freezing
  • sperm freezing
  • freezing
  • IVF
  • premature ovarian failure
  • premature ovarian insufficiency
  • testicular failure
  • ovarian tissue freezing
  • PESA
  • TESE

Related Special Issue

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

14 pages, 1025 KiB  
Review
Fertility Preservation in BRCA1/2 Germline Mutation Carriers: An Overview
by Erica Silvestris, Gennaro Cormio, Vera Loizzi, Giacomo Corrado, Francesca Arezzo and Easter Anna Petracca
Life 2024, 14(5), 615; https://doi.org/10.3390/life14050615 - 10 May 2024
Viewed by 695
Abstract
BRCA1 and BRCA2 mutations are responsible for a higher incidence of breast and ovarian cancer (from 55% up to 70% vs. 12% in the general population). If their functions have been widely investigated in the onset of these malignancies, still little is known [...] Read more.
BRCA1 and BRCA2 mutations are responsible for a higher incidence of breast and ovarian cancer (from 55% up to 70% vs. 12% in the general population). If their functions have been widely investigated in the onset of these malignancies, still little is known about their role in fertility impairment. Cancer patients treated with antineoplastic drugs can be susceptible to their gonadotoxicity and, in women, some of them can induce apoptotic program in premature ovarian follicles, progressive depletion of ovarian reserve and, consequently, cancer treatment-related infertility (CTRI). BRCA variants seem to be associated with early infertility, thus accelerating treatment impairment of ovaries and making women face the concrete possibility of an early pregnancy. In this regard, fertility preservation (FP) procedures should be discussed in oncofertility counseling—from the first line of prevention with risk-reducing salpingo-oophorectomy (RRSO) to the new experimental ovarian stem cells (OSCs) model as a new way to obtain in vitro-differentiated oocytes, several techniques may represent a valid option to BRCA-mutated patients. In this review, we revisit knowledge about BRCA involvement in lower fertility, pregnancy feasibility, and the fertility preservation (FP) options available. Full article
Show Figures

Figure 1

Back to TopTop